- JP-listed companies
- Cash flow
(E27038) Cash flow
Market cap
P/E ratio
UMN Pharma develops innovative vaccines for infectious diseases like norovirus and rotavirus while providing contract manufacturing services for biopharmaceuticals.
| 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | |
| Depreciation & amortization | 124 | 1,404 | 1,873 | 1,524 | 1,237 | - | - |
| Cash from operations | -1,188 | -3,578 | 315 | -3,394 | -2,265 | -562 | -578 |
| Capital expenditures | -8,719 | -3,894 | -5 | -407 | -1,844 | - | -161 |
| Cash from investing | -8,741 | -4,151 | -9 | -398 | -1,842 | -0 | -134 |
| Proceeds from issuance of term debt, net | 8,403 | 3,025 | - | - | - | - | - |
| Repayments of term debt | -200 | -350 | -4,920 | -336 | -1,119 | -25 | - |
| Cash from financing | 12,361 | 8,114 | -2,493 | 2,554 | 4,243 | 1,730 | -4 |